Publications by authors named "Elizabeth Plimack"

Claim this Profile
E
Editorial Comment.
Gregory Hemenway, Elizabeth R Plimack, Daniel M Geynisman

J Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Daniel D Shapiro, Edwin Jason Abel, Laurence Albiges, Dena Battle, Stephanie A Berg, Elizabeth R Plimack

Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Andrea Necchi, Matthew D Galsky, Nazli Dizman, David H Aggen, Neeraj Agarwal, Elizabeth R Plimack

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma.
Cristiane D Bergerot, David Cella, Paulo G Bergerot, Daniela V Castro, Benjamin D Mercier, Elizabeth R Plimack

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede, Elizabeth R Plimack

Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender Disparities in Citations and Altmetric Attention Score in Oncology.
Rebecca A Campbell, Emma Helstrom, Lauren Chew, Renu Eapen, Elizabeth Plimack

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial.
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, Arjun Gupta, Christopher J Sweeney, Elizabeth R Plimack

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia, Elizabeth R Plimack

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, Maxine Sun, Laurence Albiges, Elizabeth R Plimack

Eur Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.
Anumita Chakraborty, Jill Hasler, Elizabeth Handorf, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
Elizabeth R Plimack, Catherine Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu

Eur Urol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets.
Imran Safder, Henkel Valentine, Nicole Uzzo, John Sfakianos, Robert Uzzo, Elizabeth Plimack

JCO Precis Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
Irfan Cicin, Elizabeth R Plimack, Howard Gurney, Raya Leibowitz, Boris Y Alekseev

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Lucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, Sylvie Negrier, Gwénaëlle Gravis, Elizabeth R Plimack

Eur J Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation.
Laura Bukavina, Rashida Ginwala, Mohamed Eltoukhi, Mohit Sindhani, Megan Prunty, Elizabeth R Plimack

Cancer Res Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
Uttam Satyal, Henkel Valentine, David Liu, Michael Slifker, Costas D Lallas, Elizabeth R Plimack

JCO Precis Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Elizabeth R Plimack

J Natl Compr Canc Netw· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet A Bilen, Elizabeth R Plimack

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov

Eur Urol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
Pooja Ghatalia, Elizabeth R Plimack

Nat Rev Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Toni K Choueiri, Thomas Powles, Martin H Voss, Elizabeth R Plimack, Howard Gurney

Future Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov

Eur Urol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis